Sanofi SA has agreed to pay $10 million upfront to a venture-capital-led company in New Haven, Connecticut for access to ribosome-based technology to develop antibiotics for multi-drug resistant Gram-negative and Gram-positive bacteria. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
